In this video, he previews his presentation for the virtual Advances in Inflammatory Bowel Disease 2020 regional meeting on preparing patients with IBD for surgery.
Donald E. Fetterolf, MD, discusses the major advantage of amniotic membrane therapy: the ability of the allografts to attract stem cells to the region of the wound in order to rebuild damaged tissues.
Michael Banks, MD, discusses the risk for cirrhosis regression and liver cancer in patients with HCV-related cirrhosis who have already achieved SVR via DAA treatment.
